Home > Insider Trading > Filing (0001209191-14-058590)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1373707	Tetraphase Pharmaceuticals Inc	TTPH	Pharmaceutical Preparations (2834)	000000000

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1296771	Gordon John Freund	480 Arsenal St, Suite 110 Watertown MA 02472		Yes	No	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Disposition	2014-09-16	67,356	$17.03	1,367,146	No	4	S	Indirect	By Skyline Venture Management IV, LLC
Common Stock	Disposition	2014-09-17	77,000	$17.36	1,290,146	No	4	S	Indirect	By Skyline Venture Management IV, LLC

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	S	Indirect	By Skyline Venture Management IV, LLC
No	4	S	Indirect	By Skyline Venture Management IV, LLC

Footnotes

The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 17, 2014.
The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $17.00 to $17.16 per share. The reporting person hereby undertakes, upon request of the staff of the U.S. Securities and Exchange Commission, the issuer, or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
The shares are held by Skyline Venture Partners Qualified Purchaser Fund IV, L.P. ("SVP IV"). The reporting person is a member of Skyline Venture Management IV, LLC, which serves as the sole general partner of SVP IV, and may be deemed to share voting and dispositive power over the shares held by SVP IV. The reporting person disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein.
The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $17.00 to $17.62 per share. The reporting person hereby undertakes, upon request of the staff of the U.S. Securities and Exchange Commission, the issuer, or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.